P548 Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohns Disease results from a tertiary IBD centre

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalJournal of Crohn's and Colitis
DOIs
Publication statusPublished - 2024

Keywords

  • Ustekinumab
  • Crohn's disease
  • Medicine
  • Persistence (discontinuity)
  • Drug
  • Disease
  • Internal medicine
  • Dermatology
  • Pharmacology
  • Adalimumab
  • Geotechnical engineering
  • Engineering

Cite this